Category Archives: Global News Feed

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Read the original:
ObsEva Receives Nasdaq Non-Compliance Notice

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA).

Link:
Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced the signing of an agreement with YA II PN, Ltd, an exempted company incorporated in the Cayman Islands with limited liability, a company of the group of companies managed by Yorkville Advisors Global LP, its investment manager ("Yorkville"), for a financing via the issuance of convertible notes of up to CHF 20 million, to be drawn in tranches.

Continued here:
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville

Basel, Switzerland, 22 August 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm CET.

See the original post:
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19

DXS INTERNATIONAL PLC

See original here:
Annual Financial Report

MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.

Read this article:
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced its financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Go here to read the rest:
Spectral Announces Second Quarter Results and Provides Corporate Update

—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment

Excerpt from:
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Acquisition will create a vertically integrated Colorado cannabis company, significantly accelerating Bespoke’s growth strategy

View original post here:
Bespoke Extracts to Expand its Colorado Business and Capabilities with Acquisition of Best Day Ever

Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan

Go here to see the original:
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders